Ortivus AB (publ) interim report for the period July – September 2021

Ortivus expands into new markets

Highlights July – September 2021

  • Ortivus received an additional order from ST Engineering in Singapore regarding additional licenses and software adaptations. Ortivus signed a contract with ST Engineering in 2019 regarding the delivery of the MobiMed software for Singapore's ambulance service, to an order value of 27.0 MSEK. This additional order has a value of 11.7 MSEK.
  • Ortivus was awarded a contract for delivery of semi-automatic defibrillators for Region Jönköpings län's hospital operations. The value of the delivery is estimated to be 1.7 MSEK.
  • Region Örebro Län decided to prolong existing contract regarding MobiMed ePR. The total order value is 2.0 MSEK.
  • Fredrik Hovbäck ended his employment in the company and Margareta Hagman took over as interim CFO. The recruitment of a permanent CFO has been initiated.

Significant events after end of the period

  • Ortivus was awarded an additional contract for delivery of semi-automatic and manual defibrillators to Region Jönköpings Län's hospital operations. The value of the delivery is estimated to be 4.5 MSEK.
  • Ortivus and Trapeze Group entered a strategic partnerships for the Australian and New Zealand markets.

July – September 2021

  • Net sales amounted to 24.5 (25.4) MSEK.
  • The gross margin rose to 51 (31)%, during the third quarter compared to the corresponding period last year.
  • Profit after tax amounted to 2.7 (1.2) MSEK.
  • Earnings after tax per share before and after dilution amounted to 0.06 (0.03) SEK.
  • Operating cash flow amounted to 6.0 (3.1) MSEK.

January – September 2021

  • Net sales amounted to 71.7 (85.7) MSEK. During the corresponding period 2020, the turnover consisted largely of one-off deliveries, which means that the periods are not directly comparable.
  • The gross margin rose to 50 (33) %, during the third quarter compared to the corresponding period last year.
  • Profit after tax amounted to 7.6 (9.1) MSEK
  • Earnings after tax per share before and after dilution amounted to 0.17 (0.20) SEK.
  • Operating cash flow amounted to 11.5 (11.4) MSEK.
Jul-Sep 2021 Jul-Sep 2020 Jan-Sep 2021 Jan-Sep 2020 Jan-Dec 2020
Net sales (MSEK) 24.5 25.4 71.7 85.7 107.6
Gross margin (%) 51% 31% 50% 33% 36%
Operating profit (MSEK) 2.7 1.2 7.6 9.2 11.4
Operating margin (%) 11% 5% 11% 11% 11%
EBITDA (MSEK) 4.1 2.0 9.6 11.4 13.9

Contacts

For further information, please contact

Reidar Gårdebäck, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus develops and commercialises MobiMed, medical technology solutions for a safer and more efficient
healthcare. The company was founded in 1985 and is today a leading provider of mobile digital
solutions for prehospital care, worldwide. Ortivus' products are based on in-depth expertise
in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm and the company has, since 1998, a wholly-owned subsidiary based in the United Kingdom.

MobiMed is a modular platform that currently is used by over 12 000 paramedics in over 2 700 emergency vechicles. The platform consists of a monitor that in real-time measures, monitors and shares patients'
vital parameters, such as, ECG, blood pressure and blood oxygenation. The system also consists
of an electronic patient record for decision support, collection of patient data and clinical documentation.
MobiMed has a total weight of 2.5kg and is created to function in a demanding environment and out in
the field. The two-way communication supports telemedicine consulting with clinical experts while patient data is seamlessly integrated into the medical records at the hospitals and primary care centers. MobiMed saves time and helps healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-12 08:30 CET.

Attachments

Interim Report Jul Sep 2021

This entry was posted in . Bookmark the permalink.